3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 4
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
13
Carcinoma, Non-Small-Cell Lung
11
Neoplasm Metastasis
7
Brain Neoplasms
7
Rectal Neoplasms
6
Lung Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Prostatic Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Melanoma
3
Glioblastoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Laryngeal Neoplasms
2
Inflammatory Breast Neoplasms
2
Glioma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Adenocarcinoma
2
Vaginal Neoplasms
1
Interventions
Paclitaxel
23
Carboplatin
22
Capecitabine
18
Gemcitabine
16
130-nm albumin-bound paclitaxel
16
pembrolizumab
14
Cyclophosphamide
12
atezolizumab
9
Epirubicin
9
sacituzumab govitecan
8
Albumin-Bound Paclitaxel
8
eribulin
6
Vinorelbine
6
Drug Therapy
6
Doxorubicin
6
camrelizumab
4
Docetaxel
4
Cisplatin
4
Injections
3
pegfilgrastim
2
olaparib
2
famitinib
2
Filgrastim
2
Everolimus
2
veliparib
1
trilaciclib
1
toripalimab
1
taxane
1
niraparib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Triple Negative Breast Neoplasms
×
Surgical Procedures, Operative
×
Clear all
NCT02620280
2024-03-06
NeoTRIPaPDL1
Fondazione Michelangelo
Phase 3
Completed
278 enrolled